NCT03337646: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism |
|
|
| Completed | 4 | 48 | Canada | Lisdexamfetamine Dimesylate, Vyvanse | JPM van Stralen Medicine Professional, Shire | Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | 03/23 | 03/23 | | |
